Ultragenyx Pharmaceutical (RARE) Interest Expenses (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Interest Expenses data on file, last reported at $21.0 million in Q1 2026.

• On a quarterly basis, Interest Expenses rose 50.0% year-over-year to $21.0 million in Q1 2026; TTM through Mar 2026 was $68.7 million, a 12.27% increase from a year earlier, with the FY2025 full-year figure at $62.0 million, down 1.59% from the prior year.
• Interest Expenses for Q1 2026 stood at $21.0 million, up from $19.5 million in the prior quarter.
• Over the last five years, Interest Expenses for RARE reached as high as $21.0 million in Q1 2026 and fell as low as $6.6 million in Q1 2022.
• Historically, Interest Expenses has averaged $15.1 million across 5 years, with a median of $15.6 million in 2023.
• On a YoY basis, Interest Expenses climbed as much as 317.3% in 2022 and fell as far as 21.79% in 2022.
• Year by year, Interest Expenses stood at $15.9 million in 2022, then climbed by 9.13% to $17.3 million in 2023, then dropped by 10.64% to $15.5 million in 2024, then increased by 25.76% to $19.5 million in 2025, then gained by 7.86% to $21.0 million in 2026.
• Per Business Quant data, the three most recent Interest Expenses figures were $21.0 million in Q1 2026, $19.5 million in Q4 2025, and $14.1 million in Q3 2025.